Fisher s exact test for contingency tables. A two-tailed p-value <0.05 was accepted as statistically significant.

Size: px
Start display at page:

Download "Fisher s exact test for contingency tables. A two-tailed p-value <0.05 was accepted as statistically significant."

Transcription

1 BJUI A prospective, randomized trial comparing the Vienna nomogram to an eight-core prostate biopsy protocol Angus Lecuona and Chris F. Heyns Department of Urology, Tygerberg Hospital and University of Stellenbosch, Western Cape, South Africa Accepted for publication 21 July 2010 Study Type Diagnostic (RCT) Level of Evidence 1b OBJECTIVE To compare prostate cancer detection rates using the Vienna nomogram versus an 8-core prostate biopsy protocol. To compare the complication rates of transrectal prostate biopsy in the two groups. PATIENTS AND METHODS In a prospective randomized trial, men with a serum PSA 2.5 ng/ml were stratified according to serum PSA (I = PSA ; II = PSA ; III = PSA ng/ml) and were then randomized to group A (number of cores determined according to the Vienna nomogram) or group B (8-core prostate biopsy). Statistical analysis was performed using Student s t-test for parametric data, Mann- Whitney test for nonparametric data and What s known on the subject? and What does the study add? Several studies have shown that increasing the number of prostate biopsy cores will increase the detection rate of prostate cancer, but also risks overdiagnosing insignificant cancer, particularly in the elderly. Our study suggests that there is no significant advantage in using the Vienna nomogram to determine the number of prostate biopsies to be taken, compared to an eight-core biopsy protocol. Fisher s exact test for contingency tables. A two-tailed p-value <0.05 was accepted as statistically significant. RESULTS In the period July 2006 to July 2009, 303 patients were randomized to group A (n = 152) or group B (n = 151). There were no significant differences in serum PSA, prostate volume, PSA density or post-biopsy complications between the groups. The cancer detection rate was lower in group A than in group B for the whole study cohort (35.5% vs 38.4%), for those with PSA < 10 ng/ml (28.1% vs 33%) and for those with prostate volume >50 ml (22% vs 25.8%). These differences were not statistically significant (NSS). CONCLUSION These findings suggest that there is no significant advantage in using the Vienna nomogram to determine the number of prostate biopsy cores to be taken, compared to an 8-core biopsy protocol. KEYWORDS prostate cancer, prostate biopsy, Vienna nomogram INTRODUCTION With the introduction of PSA measurements and the availability of TRUS the optimal number of prostate biopsy cores has become controversial. Several studies have been performed to determine the best prostate biopsy protocol for detecting clinically significant cancer. Increasing the number of biopsy cores increases detection rates [1,2], but risks over-diagnosing insignificant cancers, and it may increase the risk of complications, whereas taking too few biopsy cores will lead to significant cancers being missed. Prostate volume is an important consideration, because too few biopsies in large prostates may fail to diagnose significant cancer [3 5]. Studies have shown that standard sextant (six-core) biopsies may be inadequate [1,3,5 7], because repeat biopsies yield cancer in a further 10 27% of cases [3,6]. A recent study from Vienna [8] proposed using a nomogram to determine the optimal number of TRUS-guided biopsy cores in men with a serum PSA level of 2 10 ng/ml, by taking into account the patient s age and prostate volume. This study compared a group of men who underwent TRUS-guided prostate biopsies according to the Vienna nomogram with a historical group who underwent eight-core biopsies. The group that underwent biopsies according to the Vienna nomogram yielded a significantly higher prostate cancer detection rate of 36.7%, compared with the historical eightcore biopsy group, in which 22% were diagnosed with prostate cancer [8]. The study from Vienna has a few shortcomings. First, it was not a prospective, randomized trial, but compared prospective use of the nomogram with eight-core biopsies obtained in a historical comparison group. The two study groups were not completely comparable with regard to mean age and serum PSA. Second, the study did not compare the risk of complications or adverse events in the two groups, i.e. it is not known whether the greater number of biopsy cores required by the Vienna nomogram results in a higher complication rate , doi: /j x x

2 RCT COMPARING THE VIENNA NOMOGRAM TO 8-CORE PROSTATE BIOPSIES Age (years) Prostate volume (ml) > TABLE 1 The Vienna nomogram [8]: number of biopsy cores based on patient age and total prostate volume were performed under local anaesthesia (periprostatic infiltration of 2% lignocaine). A Toshiba diagnostic ultrasound machine with a 6-MHz transrectal probe was used to instil the anaesthetic and to perform the prostate biopsies. Antibiotic prophylaxis was given 1 h before biopsy using 1 g ciprofloxacin followed by two 500-mg doses at 12-h intervals. TABLE 2 Analysis of whole cohort All study subjects Vienna nomogram Eight-core biopsy P value Patients (n) Age (years) 65.1 (45 82) 63.4 (40 81) * PSA level (ng/ml) 9.4 (2.2 46) 9.2 (2.6 48) Prostate volume (ml) 47.4 (11 220) 51.5 (10 194) PSA density Biopsy cores (n) 10.2 (6 18) 8 Complications, n (%) Any 45 (48.4) 43 (48.9) None 48 (51.6) 45 (51.1) Fever 4 (0.04) 5 (0.06) Urinary retention 1 (0.01) 0 (0) DRE findings Benign 124 (83.2) 115 (76.2) Suspicious or malignant 25 (16.8) 36 (23.8) Histology No prostate cancer 98 (64.5) 93 (61.6) Cancer detected 54 (35.5) 58 (38.4) Data are shown as mean and range (minimum and maximum values), unless otherwise stated. *Statistically significant; fever requiring systemic antibiotics; urinary retention secondary to gross haematuria requiring catheterization and irrigation. Statistical analysis was performed using GRAPHPAD INSTAT software with the unpaired Student s t test for parametric data, Mann Whitney U test for non-parametric data and Fisher s exact test for contingency tables. A two-tailed P-value <0.05 was accepted as significant with a power of 80%. Data are shown as mean and range (minimum and maximum values). Sample size calculation was performed using GRAPHPAD STATMATE software. The study protocol was approved by the Human Research Ethics Committee of the Faculty of Health Sciences of the University of Stellenbosch. RESULTS In the period July 2006 to July 2009, 926 patients underwent prostate biopsies at our unit. After the exclusion criteria were applied, 303 patients were randomized into group A (number of biopsy cores determined according to the Vienna nomogram, n = 152) or group B (eight-core biopsy, n = 151). The aim of our prospective, randomized trial was to determine if the Vienna nomogram would yield a higher cancer detection rate than an eight-core biopsy protocol, without incurring a higher complication rate, in a study population referred to a tertiary urology unit. PATIENTS AND METHODS Patients included in this study were men with a PSA level >2.5 ng/ml undergoing TRUSguided prostate biopsy in the Department of Urology, Tygerberg Hospital, University of Stellenbosch, South Africa. Exclusion criteria included previous prostate biopsy or surgery, previous diagnosis of prostate cancer, a history of urinary retention, previous histological evidence of prostatitis and confirmed urinary tract infection. Patients were stratified according to their serum PSA measurement into those with a low, intermediate or high risk of having prostate cancer (group I, PSA level ng/ ml; group II, ng/ml; group III, ng/ml) and then randomized using computer-generated random numbers: group A underwent TRUS-guided prostate biopsies with the number of cores determined according to the Vienna nomogram (Table 1) and group B underwent an eight-core TRUSguided prostate biopsy. All biopsy cores in both groups were taken from the lateral peripheral zone, evenly distributed from cranial to caudal. The prostate volume was measured by TRUS and biopsies The results of all study subjects and relevant subgroups are summarized in Tables 2 and 3. The mean patient age was slightly but significantly higher in the Vienna nomogram group, but there were no significant differences in serum PSA level, prostate volume, PSA density or post-biopsy complications between the groups. The overall cancer detection rate was higher in the eight-core group (38.4%) than in the Vienna nomogram group (35.5%) but this difference was not significant (NS) (Table 2). The proportion of patients with DRE findings suspicious of malignancy was slightly higher in the eight-core group (23.8% vs 16.8%, NS). This discrepancy may be ascribed to the fact that study subjects were not stratified according to DRE findings before randomization. When controlling for this difference in the subgroup

3 LECUONA and HEYNS of subjects with PSA level <10 ng/ml and benign DRE the cancer detection rate was still higher in the eight-core group (26.9% vs 21.6%; NS). Analysis of different subgroups (PSA level <10 ng/ml, DRE benign plus PSA level <10 ng/ml, prostate volume >50 ml, age <60 or >70 years) showed no significant differences in the cancer detection rates between the Vienna nomogram and eight-core biopsy groups (Table 3) There were no significant differences between the two groups (overall or in any subgroup) as far as complications experienced were concerned. Only minor complications were reported, with self-limiting macroscopic haematuria being the most common. Other complications included haematospermia, haematochezia, dysuria, painful ejaculation and fever. DISCUSSION McNeal [9] described the different zones of the prostate in 1969 and commented on the origin and spread of prostate cancer in the peripheral zone. Hodge et al. [10] introduced systematic sextant biopsy of the prostate under TRUS guidance in These six biopsies were distributed evenly, from cranial to caudal in the mid-lobar, parasagittal plane. Stamey [11] suggested placing these biopsy cores more laterally to better sample the peripheral zone. Several authors have shown that biopsies of the transition zone do not increase cancer detection rates [12]. In 2005, Remzi and colleagues developed the Vienna nomogram (Table 1), using data from the European Prostate Cancer Detection study [3,8]. The nomogram indicates the optimum number of cores to be taken during prostate biopsy, based on patient age and total prostate volume. The objective of the nomogram is to increase prostate cancer detection rates in younger men and those with larger prostates (so decreasing the number of repeat biopsies) and to avoid detection of insignificant cancers in older patients. In a prospective study of 502 men (PSA level 2 10 ng/ml) the overall cancer detection rate was 36.7% [8]. The mean number of cores taken, patient age, total prostate volume and TABLE 3 Analysis of subgroups Vienna nomogram Eight-core biopsy P value Subgroup PSA level <10 ng/ml Age (years) 64.9 (45 79) 62.7 (40 78) * PSA level (ng/ml) 5.8 ( ) 5.7 ( ) Prostate volume (ml) 47.4 (11 220) 46.0 (10 194) PSA density 0.16 ( ) 0.16 ( ) DRE findings, n (%) Benign 102 (91.1) 93 (83.0) Suspicious or malignant 10 (8.9) 19 (17.0) Biopsy cores (n) 10.3 (6 18) 8 No prostate cancer 82 (71.9) 75 (67) Cancer detected 32 (28.1) 37 (33) Subgroup DRE findings benign and PSA level <10 ng/ml No prostate cancer 80 (78.4) 68 (73.1) Cancer detected 22 (21.6) 25 (26.9) Subgroup: prostate volume >50 ml No prostate cancer 39 (78) 46 (74.2) Cancer detected 11 (22) 16 (25.8) Complications, n (%) Any 16 (59.3) 14 (37.8) None 11 (40.7) 23 (62.2) Subgroup: age <60 years No prostate cancer 26 (63.4) 32 (61.5) Cancer detected 15 (36.6) 20 (38.5) Biopsy cores (n) Subgroup: age >70 years No prostate cancer 29 (67.4) 17 (53.1) Cancer detected 14 (32.6) 15 (46.9) Biopsy cores (n) Data are shown as mean and range (minimum and maximum values) unless otherwise stated. *Statistically significant. PSA measurement were 10, 65 years, 43 ml and 5.5 ng/ml, respectively. On multivariate analysis, prostate volume was not an independent predictor of prostate cancer detection, so eliminating the sampling error caused by large prostates by taking more cores. This prospective study also compared well against data from the European Prostate Cancer Detection study [3], where the cancer detection rate was 22% on first biopsy and 10% on repeat biopsy, using an eight-core biopsy. During the study, 926 patients underwent prostate biopsies at our unit, of whom 303 were included. The rationale for excluding patients with UTI, urinary retention or previous prostatic procedures was to exclude those with a falsely raised PSA level. The fact that 623 patients were excluded from the study reflects our referral patient profile, where most men present with advanced prostate cancer disease or complications of BPH such as UTI or retention. In the present study the cancer detection rate was higher in the eight-core biopsy group than in the Vienna nomogram group for the whole study cohort (38.4% vs 35.5%), for those with a PSA reading <10 ng/ml (33%

4 RCT COMPARING THE VIENNA NOMOGRAM TO 8-CORE PROSTATE BIOPSIES versus 28.1%), for those with prostate volume >50 ml (25.8% vs 22%) and for those with both PSA level <10 ng/ml and clinical BPH (26.9% vs 21.6%) (Tables 2 and 3). However, these differences were small and not significant. The mean PSA values of the two groups were 9.4 ng/ml (Vienna nomogram group) vs 9.2 ng/ml (Control group), and reflect all patients with PSA levels between 2.5 and 50 ng/ml. Most patients had a PSA level <10 ng/ml (n = 226; 75%) with a mean of 5.8 ng/ml in the Vienna nomogram group compared with 5.7 ng/ml in the control group. The two groups are comparable in all aspects except age, for which the Vienna nomogram group has a mean age of 64.9 years vs 62.7 years in the control group. This subgroup (PSA level ng/ml) is also comparable to the patients in the original Vienna nomogram article (Table 3). Findings on DRE were more often suspicious of malignancy in the eight-core group than in the Vienna nomogram group for the whole cohort and subgroups. This discrepancy between the two groups occurred by chance, despite stratification according to serum PSA, and probably explains the higher cancer detection rate in group B. However, even when controlling for this, the eightcore biopsy protocol still detected more prostate cancer than the Vienna nomogram group, although the difference was not significant. Several authors have shown that increasing the number of prostate biopsies increases the cancer detection rate [1,13 15]. The use of extended biopsy protocols eventually led to saturation biopsy schemes [6,7], which involve taking cores in one sitting. These biopsy schemes particularly target the lateral peripheral zone and apex of the prostate. As an initial biopsy strategy, Jones et al. [16] did not find saturation biopsies useful. In a cohort of 139 patients who underwent saturation biopsies (24 cores), 44.6% were diagnosed with prostate cancer, compared with a 51.7% detection rate in a historical comparison group (10 cores) consisting of 87 patients. Guichard et al. [17] published a series of 1000 consecutive patients. The cancer detection rates of the 6-, 12-, 18- and 21-core biopsy strategies were 31.7%, 38.7%, 41.5% and 42.5%, respectively, in patients who underwent first-time biopsies. Other authors [18] had similar results of a 40% cancer detection rate, using saturation biopsy techniques for firsttime biopsies. However, saturation biopsies have proven effective when used in the repeat biopsy scenario [19,20]. Recently, concerns have been raised regarding the potential under-sampling of larger glands by the traditional sextant biopsy protocol [3 5]. One of the aims of the Vienna nomogram is to increase prostate cancer detection by increasing the number of cores taken at biopsy of larger prostates (Table 1). In our study, in the subgroup of patients with a prostate volume >50 ml, prostate cancer detection was higher in the eight-core group (25.8%) compared with the Vienna nomogram group (22%; mean number of cores taken 14.4), but this difference was not significant (Table 3). Given the high prevalence of histological prostate cancer [21], the increased detection due to (i) structured screening studies, (ii) a greater awareness of prostate cancer among the general public, (iii) a reduction in PSA thresholds for biopsy, (iv) an increase in the number of biopsy cores [22] and (v) the long lead-time of prostate cancer, the risk of overdiagnosis and overtreatment is substantial [23]. Another aim of the Vienna nomogram is to reduce the likelihood of detecting insignificant prostate cancer, by reducing the number of biopsies taken from older patients. Criteria which could indicate clinically insignificant prostate cancer, and which could be used in active surveillance of patients, include: a Gleason score 6 (no pattern 4 or 5 disease), PSA level 10 ng/ml, clinical stage T1 or T2a disease, PSA density 0.15, percentage positive biopsy cores <33%, <50% involvement of any biopsy core and stable PSA kinetics [24 26]. Using the above definition, only 14 (4.6%) of the 303 patients in our study had insignificant prostate cancer, 5/152 (3.3%) in the Vienna nomogram group and 9/151(6.0%) in the control group. Unfortunately, no conclusions can be drawn from so few patients, except that insignificant prostate cancer is extremely rare in our referral population. In our study, more patients were diagnosed with prostate cancer in the age group >70 years, using the eight-core biopsy protocol compared with the Vienna nomogram (46.9% vs 32.6%; NS). The mean number of cores taken with the Vienna nomogram in patients older than 70 years was 8.5. Increasing the number of prostate biopsy cores raises the concern of increased morbidity. TRUS-guided biopsies of the prostate are associated with several minor but self-limiting complications and are usually well tolerated by patients [27]. In our study the complication rates in the two groups overall were almost identical (Table 2). Patients in the subgroup with prostate volume >50 ml had a higher complication rate in the Vienna nomogram group (average of 14.4 cores) than in the eight-core group (59.3% vs 37.8, NS) (Table 3). These complications were minor, consisting mostly of self-limiting macroscopic haematuria. Serious complications were rare: four patients in the Vienna nomogram group and five patients in the control group developed post-biopsy fever requiring parenteral antibiotic treatment at their local hospital or general practitioner. All patients had an uneventful recovery. One patient in the Vienna nomogram group (16 cores) developed urinary retention secondary to gross haematuria that required catheterization and irrigation for 2 days (Table 2). The main limitation of this study is that stratification before randomization was performed according to serum PSA level alone and did not include DRE, with the result that, by chance, a greater proportion of subjects with DRE findings suspicious of malignancy were included in group B, but controlling for this discrepancy did not reveal a significant difference in cancer detection. The main objective of this prospective, randomized study was to determine whether the Vienna nomogram (which was originally developed in a screening setting) would be useful, when applied in a urology referral unit. Overall, when comparing the results from biopsies taken using the Vienna nomogram versus an eight-core biopsy protocol, no significant differences were noted in the cancer detection or complication rates. CONFLICT OF INTEREST None declared

5 LECUONA and HEYNS REFERENCES 1 Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: Ravery V, Goldblatt L, Royer B, Blanc E, Toublanc M, Boccon-Gibod L. Extensive biopsy protocol improves the detection rate of prostate cancer. J Urol 2000; 164: Djavan B, Zlotta A, Remzi M et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000; 163: Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughn ED Jr. The influence of prostate size on cancer detection. Urology 1995; 46: Remzi M, Djavan B, Wammack R et al. Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? Urology 2003; 61: Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol 2000; 163: Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166: 86 91; discussion Remzi M, Fong YK, Dobrovits M et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005; 174: McNeal JE. Origin and development of carcinoma of the prostate. Cancer 1969; 23: Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995; 45: Pelzer AE, Bektic J, Berger AP et al. Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the Tyrol screening project. Eur Urol 2005; 48: Philip J, Ragavan N, Desouza J, Foster CS, Javle P. Effect of peripheral biopsies in maximising early prostate cancer detection in 8-, 10- or 12-core biopsy regimens. BJU Int 2004; 93: Presti JC, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000; 163: Inahara M, Suzuki H, Kojima S et al. Improved prostate cancer detection using systematic 14-core biopsy for large glands with normal digital rectal examination findings. Urology 2006; 68: Jones JS, Patel A, Schoenfield L, Rabets JC, Zippe CD, Magi-Galluzzi C. Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol 2006; 175: Guichard G, Larré S, Gallina A et al. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol 2007; 52: Descazeaud A, Rubin M, Chemama S et al. Saturation biopsy protocol enhances prediction of pt3 and surgical margin status on prostatectomy specimen. World J Urol 2006; 24: Walz J, Graefen M, Chun FK et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006; 50: Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007; 52: Sakr WA, Grignon DJ, Crissman JD et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20 69: an autopsy study of 249 cases. In Vivo 1994; 8: Bangma CH, Roemeling S, Schröder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007; 25: Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostatespecific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: Dall Era MA, Cooperberg MR, Chan JM et al. Active surveillance for early-stage prostate cancer. Cancer 2008; 112: O Donnell H, Parker C. What is low-risk cancer and what is its natural history? World J Urol 2008; 26: Paul R, Schöler S, van Randenborgh H, Kübler H, Alschibaja M, Busch R. Morbidity of prostatic biopsy for different biopsy strategies: is there a relation to core number and sampling region? Eur Urol 2004; 45: Correspondence: Angus Lecuona, Tygerberg Hospital, University of Stellenbosch, Department of Urology, Room th Floor, Clinical Building Faculty of Health Sciences Tygerberg Western Cape 7505, South Africa. Abbreviation: NS, not significant

Are extended biopsies really necessary to improve prostate cancer detection?

Are extended biopsies really necessary to improve prostate cancer detection? (2003) 6, 250 255 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Are extended biopsies really necessary to improve prostate cancer detection? R Damiano*,1, R

More information

Introduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer

Introduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril

More information

Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels

Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels DOI: 10.1111/j.1745-7262.2008.00345.x www.asiaandro.com. Clinical Experience. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels Bo Dai 1,4, Ding-Wei

More information

Oncology: Prostate/Testis/Penis/Urethra

Oncology: Prostate/Testis/Penis/Urethra 0022-5347/04/1724-1297/0 Vol. 172, 1297 1301, October 2004 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2004 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000139993.51181.5d Oncology: Prostate/Testis/Penis/Urethra

More information

Active Surveillance for Management of Low Grade Prostate Cancer. Kelly J. Casperson, M.D. General Surgery Grand Rounds Resident Debate 11/24/2008

Active Surveillance for Management of Low Grade Prostate Cancer. Kelly J. Casperson, M.D. General Surgery Grand Rounds Resident Debate 11/24/2008 Active Surveillance for Management of Low Grade Prostate Cancer Kelly J. Casperson, M.D. General Surgery Grand Rounds Resident Debate 11/24/2008 Purpose of Debate Discuss current clinical practice and

More information

PROSTATE ULTRASOUND: Detection of Tumor& Biopsy. Ewa Kuligowska, M.D.

PROSTATE ULTRASOUND: Detection of Tumor& Biopsy. Ewa Kuligowska, M.D. PROSTATE ULTRASOUND: Detection of Tumor& Biopsy Ewa Kuligowska, M.D. PROSTATE CANCER Prostate cancer continues to be the most common lethal malignancy in American men is the second leading cause of cancerrelated

More information

of Nebraska - Lincoln

of Nebraska - Lincoln University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Department of Veterans Affairs Staff Publications U.S. Department of Veterans Affairs 8-2000 Detection, Characterization,

More information

Prostate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive ( ct2) patients

Prostate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive ( ct2) patients ORIGINAL ARTICLE Vol. 40 (5): 613-619, September - October, 2014 doi: 10.1590/S1677-5538.IBJU.2014.05.05 Prostate volume predicts high grade prostate cancer both in digital rectal examination negative

More information

Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection

Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection DOI 10.1186/s40064-016-3176-3 RESEARCH Open Access Developing a new score system for patients with PSA ranging from 4 to 20 ng/ ml to improve the accuracy of PCa detection Yuxiao Zheng, Yuan Huang, Gong

More information

PROSTATE SPECIFIC ANTIGEN

PROSTATE SPECIFIC ANTIGEN PROSTATE SPECIFIC ANTIGEN CARCINOMA OF THE PROSTATE CLINICAL CORRELATION DIAGNOSIS OFTEN OCCULT CLINICALLY INAPPARENT MICROSCOPIC LESIONS AT AUTOPSY OR RANDOM BIOPSY 30% OF ALL 50 Y/O MEN; UP TO 70% OF

More information

Pre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest

Pre-test. Prostate Cancer The Good News: Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest Pre-test Matthew R. Cooperberg, MD, MPH UCSF 40 th Annual Advances in Internal Medicine Prostate Cancer Screening 2012: Putting the PSA Controversy to Rest 1. I do not offer routine PSA screening, and

More information

Prostate Case Scenario 1

Prostate Case Scenario 1 Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has

More information

Published Ahead of Print on April 4, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION

Published Ahead of Print on April 4, 2011 as /JCO J Clin Oncol by American Society of Clinical Oncology INTRODUCTION Published Ahead of Print on April 4, 2011 as 10.1200/JCO.2010.32.8112 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2010.32.8112 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E

More information

Real-time Elastography for the Diagnosis of Prostate Cancer: Evaluation of Elastographic Moving Images

Real-time Elastography for the Diagnosis of Prostate Cancer: Evaluation of Elastographic Moving Images Real-time Elastography for the Diagnosis of Prostate Cancer: Evaluation of Elastographic Moving Images Tomoaki Miyagawa 1, Masakazu Tsutsumi 2, Takeshi Matsumura 3, Natsui Kawazoe 2, Satoru Ishikawa 2,

More information

Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients

Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients Pietro Pepe, Francesco Aragona To cite this version: Pietro Pepe, Francesco Aragona.

More information

Undergrading and Understaging in Patients with Clinically Insignificant Prostate Cancer who Underwent Radical Prostatectomy

Undergrading and Understaging in Patients with Clinically Insignificant Prostate Cancer who Underwent Radical Prostatectomy Clinical Urology Clinically Insignificant Prostate Cancer International Braz J Urol Vol. 36 (3): 292-299, May - June, 2010 doi: 10.1590/S1677-55382010000300005 Undergrading and Understaging in Patients

More information

Radical prostatectomy is the most widely used treatment. Partial Sampling of Radical Prostatectomy Specimens

Radical prostatectomy is the most widely used treatment. Partial Sampling of Radical Prostatectomy Specimens ORIGINAL ARTICLE Detection of Positive Margins and Extraprostatic Extension Viacheslav Iremashvili, MD, PhD,* Soum D. Lokeshwar,* Mark S. Soloway, MD,* Lise tpelaez,md,w Saleem A. Umar, MD,w Murugesan

More information

Active Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it fool-proof?

Active Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it fool-proof? Active Surveillance with High Resolution Color-Doppler Transrectal Ultrasound Monitoring: Is it fool-proof? Duke Bahn MD Prostate Institute of America, Ventura, California INTRODUCTION In the November

More information

Prostatic ductal adenocarcinoma: An aggressive variant that is underdiagnosed and undersampled on transrectal ultrasound (TRUS)-guided needle biopsy

Prostatic ductal adenocarcinoma: An aggressive variant that is underdiagnosed and undersampled on transrectal ultrasound (TRUS)-guided needle biopsy Original research Prostatic ductal adenocarcinoma: An aggressive variant that is underdiagnosed and undersampled on transrectal ultrasound (TRUS)-guided needle biopsy Previn Gulavita, MD; * Shaheed W.

More information

Ductal adenocarcinoma of the prostate: A clinicopathological study

Ductal adenocarcinoma of the prostate: A clinicopathological study 20 B. SATHESAN, S. A. S. GOONEWARDENA, H. W. D. ANURUDDHIKA AND M. V. C. DE SILVA Sri Lanka Journal of Urology, 2008, 9, 20-24 Original Article Ductal adenocarcinoma of the prostate: A clinicopathological

More information

Are Prostate Carcinoma Clinical Stages T1c and T2 Similar?

Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Clinical Urology Are Clinical Stages T1c and T2 Similar? International Braz J Urol Vol. 32 (2): 165-171, March - April, 2006 Are Prostate Carcinoma Clinical Stages T1c and T2 Similar? Athanase Billis,

More information

Serum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study

Serum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study european urology 51 (2007) 1645 1653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia Serum Prostate-Specific Antigen as a Predictor of Prostate

More information

Increasing Hospital Admission Rates for Urological Complications After Transrectal Ultrasound Guided Prostate Biopsy

Increasing Hospital Admission Rates for Urological Complications After Transrectal Ultrasound Guided Prostate Biopsy Increasing Hospital Admission Rates for Urological Complications After Transrectal Ultrasound Guided Prostate Biopsy Robert K. Nam,*, Refik Saskin, Yuna Lee, Ying Liu, Calvin Law, Laurence H. Klotz, D.

More information

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION VOLUME 28 NUMBER 1 APRIL 1 21 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Risk Factors for Prostate Cancer Detection After a Negative Biopsy: A Novel Multivariable Longitudinal Approach Peter

More information

Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients

Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients (2003) 6, 256 260 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Age-specific reference ranges for prostate-specific antigen (PSA) in Jordanian patients 1, *

More information

ACTIVE SURVEILLANCE FOR PROSTATE CANCER

ACTIVE SURVEILLANCE FOR PROSTATE CANCER ACTIVE SURVEILLANCE FOR PROSTATE CANCER Dr. Michael J Metcalfe PGY-2 Department of Urological Sciences April 25, 2012 CASE RM 65 year old active Caucasian male, married. PSA= 7.0 T2a Gleason 3+3=6 2/6

More information

EUROPEAN UROLOGY 58 (2010)

EUROPEAN UROLOGY 58 (2010) EUROPEAN UROLOGY 58 (2010) 369 373 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance

More information

Complexed Prostate-specific Antigen for the Detection of Prostate Cancer

Complexed Prostate-specific Antigen for the Detection of Prostate Cancer Complexed Prostate-specific Antigen for the Detection of Prostate Cancer XAVIER FILELLA 1, DAVID TRUAN 2, JOAN ALCOVER 2, RAFAEL GUTIERREZ 2, RAFAEL MOLINA 1, FRANCISCA COCA 1 and ANTONIO M. BALLESTA 1

More information

Clinically localized prostate cancer is associated with a wide variation

Clinically localized prostate cancer is associated with a wide variation 971 The Clinical Management of Patients With a Small Volume of Prostatic Cancer on Biopsy: What Are the Risks of Progression? A Systematic Review and Meta-analysis Patricia Harnden, MD, PhD 1 Brian Naylor,

More information

A retrospective study of prostate cancer cases mimicking urothelial cell carcinoma of the bladder

A retrospective study of prostate cancer cases mimicking urothelial cell carcinoma of the bladder Liu et al. European Journal of Medical Research 2013, 18:36 EUROPEAN JOURNAL OF MEDICAL RESEARCH RESEARCH Open Access A retrospective study of prostate cancer cases mimicking urothelial cell carcinoma

More information

Efficacy of Pelvic Diffusion Weighted MRI Prior to Prostate Biopsy in Patients with tpsa Level of 2,5-20 ng/ml for Determination of Malign Lesions

Efficacy of Pelvic Diffusion Weighted MRI Prior to Prostate Biopsy in Patients with tpsa Level of 2,5-20 ng/ml for Determination of Malign Lesions ISPUB.COM The Internet Journal of Urology Volume 14 Number 1 Efficacy of Pelvic Diffusion Weighted MRI Prior to Prostate Biopsy in Patients with tpsa Level of 2,5-20 ng/ml for Determination of Malign Lesions

More information

Hypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings

Hypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings Hypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings Hak Jong Lee, MD 1 Ghee Young Choe, MD 2 Chang Gyu Seong, MD 3 Seung Hyup Kim, MD 4 Index terms: Prostate Prostate,

More information

UC San Francisco UC San Francisco Previously Published Works

UC San Francisco UC San Francisco Previously Published Works UC San Francisco UC San Francisco Previously Published Works Title The quantitative Gleason score improves prostate cancer risk assessment Permalink https://escholarship.org/uc/item/9wq7g6k5 Journal Cancer,

More information

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.

NIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1. NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low

More information

Department of Urology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy 2

Department of Urology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy 2 Oncology Volume 2012, Article ID 645146, 6 pages doi:10.1155/2012/645146 Research Article Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level

More information

Authors KC Cheng, LF Lee, KW Wong, HC Chan, CL Cho, H Chau, KM Lam, HS So. Division of Urology, Department of Surgery, United Christian Hospital

Authors KC Cheng, LF Lee, KW Wong, HC Chan, CL Cho, H Chau, KM Lam, HS So. Division of Urology, Department of Surgery, United Christian Hospital Efficacy of Routine Screening of Urine Culture before Transurethral Prostatectomy on the Improvement of the Post Operative Outcome - a Single Centre Experience Authors KC Cheng, LF Lee, KW Wong, HC Chan,

More information

3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships

3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships Disclosure of Relevant Financial Relationships Staging and Reporting of Prostate Cancer: Major Changes in 8 th Edition AJCC Staging and CAP Cancer Checklists USCAP requires that all planners (Education

More information

Sorveglianza Attiva update

Sorveglianza Attiva update Sorveglianza Attiva update Dr. Sergio Villa Dr. Riccardo Valdagni www.thelancet.com Published online August 7, 2014 http://dx.doi.org/10.1016/s0140-6736(14)60525-0 the main weakness of screening is a high

More information

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,

More information

Using Gray-Scale and Color and Power Doppler Sonography to Detect Prostatic Cancer

Using Gray-Scale and Color and Power Doppler Sonography to Detect Prostatic Cancer Using Gray-Scale and Color and Power Doppler Sonography to Detect Prostatic Cancer Ethan J. Halpern 1 Stephen E. Strup 2 OBJECTIVE. We performed a prospective study to assess gray-scale and color and power

More information

Prostate cancer smart screening, precision diagnosis, personalised treatment'

Prostate cancer smart screening, precision diagnosis, personalised treatment' Prostate cancer smart screening, precision diagnosis, personalised treatment' Prof. Hashim Ahmed PhD, FRCS(Urol), BM, BCh (Oxon), BA(Hons) Consultant Urological Surgeon Bupa Cromwell Hospital Clinics:

More information

Ambulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer

Ambulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer Ambulatory and Office Urology Optimal Measure of PSA Kinetics to Identify Prostate Cancer Luigi Benecchi, Anna Maria Pieri, Carmelo Destro Pastizzaro, and Michele Potenzoni OBJECTIVES METHODS RESULTS CONCLUSIONS

More information

Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance

Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance & 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance Charles C Guo 1 and

More information

The accuracy of prostate biopsy to assign patients with low-grade prostate cancer to active surveillance

The accuracy of prostate biopsy to assign patients with low-grade prostate cancer to active surveillance Boston University OpenBU Theses & Dissertations http://open.bu.edu Boston University Theses & Dissertations 2014 The accuracy of prostate biopsy to assign patients with low-grade prostate cancer to active

More information

Clinical Cancer Investigation Journal

Clinical Cancer Investigation Journal ISSN 2278-1668 Middle-Eastern Association for Cancer Research Clinical Cancer Investigation Journal Volume 4, Issue 5, September-October 2015 Clinical Cancer Investigation Journal An official publication

More information

Date Modified: March 31, Clinical Quality Measures for PQRS

Date Modified: March 31, Clinical Quality Measures for PQRS Date Modified: March 31, 2015 2015 Clinical Quality s for PQRS # Domain Title Description Type Denominator Numerator Denominator Exclusions/Exceptions 1 Patient Safety Prostate Biopsy Antibiotic Process

More information

Prostate Cancer Incidence

Prostate Cancer Incidence Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases

More information

Multiple Vesico-Urethral Biopsies Following Radical Prostatectomy: The Predictive Roles of TRUS,DRE, PSA and the Pathological Stage

Multiple Vesico-Urethral Biopsies Following Radical Prostatectomy: The Predictive Roles of TRUS,DRE, PSA and the Pathological Stage European Urology European Urology 44 (2003) 407 414 Multiple Vesico-Urethral Biopsies Following Radical Prostatectomy: The Predictive Roles of TRUS,DRE, PSA and the Pathological Stage Vincenzo Scattoni

More information

AGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN IN BLACK MEN. The New England Journal of Medicine

AGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN IN BLACK MEN. The New England Journal of Medicine AGE-SPECIFIC REFERENCE RANGES FOR SERUM PROSTATE-SPECIFIC ANTIGEN IN BLACK MEN TED O. MORGAN, M.D., STEVEN J. JACOBSEN, M.D., PH.D., WILLIAM F. MCCARTHY, PH.D., DEBRA J. JACOBSON, M.S., DAVID G. MCLEOD,

More information

Invasion of the muscular wall of the seminal vesicles by prostate cancer is generally

Invasion of the muscular wall of the seminal vesicles by prostate cancer is generally PROSTATE CANCER Seminal Vesicle Invasion by Prostate Cancer: Prognostic Significance and Therapeutic Implications Steven R. Potter, MD,* Jonathan I. Epstein, MD,* Alan W. Partin, MD, PhD* *The James Buchanan

More information

Accepted for publication 3 January 2005

Accepted for publication 3 January 2005 Original Article RACIAL DIFFERENCES IN PSA DOUBLING TIME AND RECURRENCE TEWARI et al. In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several

More information

Radiation Therapy After Radical Prostatectomy

Radiation Therapy After Radical Prostatectomy Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg

More information

2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE. Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT

2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE. Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT 2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT 2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE AUTHORS : PROSTATE CHAPTER

More information

Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC

Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,

More information

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology

Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology Pathology of Prostate Gland Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology Normal Anatomy Review Anatomy

More information

The Prostate Specific-Antigen (PSA):

The Prostate Specific-Antigen (PSA): The Prostate Specific-Antigen (PSA): Why it could not detect prostate cancer reliably in the past and How it became a sensitive and specific tumor marker Hans H. Glaettli, dipl. Phys. ETH 0. Summary PSA

More information

Effect on hemostasis of an absorbable hemostatic gelatin sponge after transrectal prostate needle biopsy

Effect on hemostasis of an absorbable hemostatic gelatin sponge after transrectal prostate needle biopsy ORIGINAL ARTICLE Vol. 41 (2): 337-343, March - April, 2015 doi: 10.1590/S1677-5538.IBJU.2015.02.22 Effect on hemostasis of an absorbable hemostatic gelatin sponge after transrectal prostate needle biopsy

More information

Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer?

Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer? Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer? Megumi Hirobe 1, Atsushi Takahashi 1, Shin-ichi Hisasue 1, Hiroshi Kitamura 1, Yasuharu Kunishima 1, Naoya Masumori 1, Akihiko

More information

False-positive screening results in the European randomized study of screening for prostate cancer

False-positive screening results in the European randomized study of screening for prostate cancer E U RO P E A N J O U R NA L O F CA N C E R47 (2011) 2698 2705 available at www.sciencedirect.com journal homepage: www.ejconline.com False-positive screening results in the European randomized study of

More information

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of

More information

Diagnostic TRUS Elastography of the Prostate

Diagnostic TRUS Elastography of the Prostate Diagnostic TRUS Elastography of the Prostate George Zacharopoulos Department of Diagnostic Ultrasound Hygeia Hospital Athens, Greece Prostate HI-RTE Why we need Elastography Better Detection of possible

More information

Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy

Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory

More information

Disease State Prostatitis Indicator Classification Disease Management Strength of Recommendation

Disease State Prostatitis Indicator Classification Disease Management Strength of Recommendation Client HMSA: PQSR 2009 Measure Title DIAGNOSTIC WORKUP OF CHRONIC PROSTATITIS Disease State Prostatitis Indicator Classification Disease Management Strength of Recommendation B Organizations Providing

More information

Prostate MRI for local staging and surgical planning in prostate cancer

Prostate MRI for local staging and surgical planning in prostate cancer Prostate MRI for local staging and surgical planning in prostate cancer 15th Annual Floyd A. Fried Advances in Urology Symposium June 23, 2017 Ray Tan, MD, MSHPM Assistant Professor Disclosures None Objectives

More information

Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate

Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate Article ID: WMC003222 ISSN 2046-1690 Serum PSA, Gleason Score and Clinical Staging in Predicting Biochemical (PSA) Failure After Radical Prostatectomy for Carcinoma of Prostate Corresponding Author: Mr.

More information

Introduction. American Society of Clinical Oncology All rights reserved.

Introduction.  American Society of Clinical Oncology All rights reserved. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement This is an endorsement

More information

Cystoscopy in children presenting with hematuria should not be overlooked

Cystoscopy in children presenting with hematuria should not be overlooked Ped Urol Case Rep 2015; 2(3):7-11 DOI: 10.14534/PUCR.2015310303 PUCR Ped Urol Case Rep PEDIATRIC UROLOGY CASE REPORTS ISSN: 2148 2969 Journal homepage: http://www.pediatricurologycasereports.com Cystoscopy

More information

Potency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery

Potency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery Potency after unilateral nerve sparing surgery: a report on functional and oncological results of unilateral nerve sparing surgery F Van der Aa 1, S Joniau 1, D De Ridder 1 & H Van Poppel 1 * 1 Department

More information

Clinical Case Conference

Clinical Case Conference Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3

More information

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma

Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,

More information

Prostate Cancer Screening. Dickon Hayne University of Western Australia

Prostate Cancer Screening. Dickon Hayne University of Western Australia Prostate Cancer Screening Dickon Hayne University of Western Australia JMG Wilson & G Junger, WHO, 1968 p26-27 In theory, therefore, screening is an admirable method of combating disease, since it should

More information

Introduction. HP Beerlage 1 *, RG Aarnink 1, ETh Ruijter 2, JA Witjes 1, H Wijkstra 1, CA van de Kaa 2, FMJ Debruyne 1 & JJMCH de la Rosette 1

Introduction. HP Beerlage 1 *, RG Aarnink 1, ETh Ruijter 2, JA Witjes 1, H Wijkstra 1, CA van de Kaa 2, FMJ Debruyne 1 & JJMCH de la Rosette 1 (2001) 4, 56±62 ß 2001 Nature Publishing Group All rights reserved 1365±7852/01 $15.00 www.nature.com/pcan Correlation of transrectal ultrasound, computer analysis of transrectal ultrasound and histopathology

More information

Is Age an Independent Factor for Prostate Cancer? A Paired Analysis

Is Age an Independent Factor for Prostate Cancer? A Paired Analysis Original Paper DOI: 10.1159/000447138 Received: November 11, 2015 Accepted: December 28, 2015 Published online: December 26, 2016 Is Age an Independent Factor for Prostate Cancer? A Paired Analysis José

More information

Development and Validation of a Nomogram to Estimate the Risk of Prostate Cancer in Brazil

Development and Validation of a Nomogram to Estimate the Risk of Prostate Cancer in Brazil Development and Validation of a Nomogram to Estimate the Risk of Prostate Cancer in Brazil THIAGO B. SILVA 1, CLEYTON Z. OLIVEIRA 2, ELINEY F. FARIA 3, EDMUNDO C. MAUAD 1, KARI J. SYRJÄNEN 2,4 and ANDRÉ

More information

Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer

Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department

More information

The PSA Controversy. What are we doing? Erin T. Bird, MD, MBA

The PSA Controversy. What are we doing? Erin T. Bird, MD, MBA The PSA Controversy What are we doing? Erin T. Bird, MD, MBA Associate Professor of Surgery Chief, Section of Genitourinary Reconstruction and Voiding Dysfunction Division of Urology Scott & White Healthcare

More information

Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone

Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone (2002) 5, 279 284 ß 2002 Nature Publishing Group All rights reserved 1365 7852/02 $25.00

More information

Clinical audit. symptoms in general practice. An audit of prostate-specific antigen and clinical

Clinical audit. symptoms in general practice. An audit of prostate-specific antigen and clinical Postgrad MedJ 1998;74:28-32 c The Fellowship of Postgraduate Medicine, 1998 Clinical audit An audit of prostate-specific antigen and clinical symptoms in general practice S Ramachandran, MC Foster, DR

More information

ACTIVE SURVEILLANCE OF SMALL RENAL MASSES. Alessandro VOLPE, M.D.

ACTIVE SURVEILLANCE OF SMALL RENAL MASSES. Alessandro VOLPE, M.D. BAUS section of Oncology Annual Meeting London Sep 15-16, 2014 ACTIVE SURVEILLANCE OF SMALL RENAL MASSES Alessandro VOLPE, M.D. University of Eastern Piedmont Amedeo Avogadro Maggiore della Carità Hospital

More information

NEGATIVE BIOPSIES WITH RISING PROSTATE-SPECIFIC ANTIGEN. WHAT TO DO?

NEGATIVE BIOPSIES WITH RISING PROSTATE-SPECIFIC ANTIGEN. WHAT TO DO? NEGATIVE BIOPSIES WITH RISING PROSTATE-SPECIFIC ANTIGEN. WHAT TO DO? *Juan Gómez Rivas, 1 Mario Alvarez-Maestro, 1 Marcin Czarniecki, 2 Stefan Czarniecki, 3 Moises Rodriguez Socarras, 4 Stacy Loeb 5 1.

More information

ISSN: (Print) (Online) Journal homepage:

ISSN: (Print) (Online) Journal homepage: Archives of Andrology Journal of Reproductive Systems ISSN: 0148-5016 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/iaan19 CHANGE IN INTERNATIONAL PROSTATE SYMPTOM SCORE AFTER TRANSURETHRAL

More information

The Contemporary Concept of Significant Versus Insignificant Prostate Cancer

The Contemporary Concept of Significant Versus Insignificant Prostate Cancer EUROPEAN UROLOGY 60 (2011) 291 303 available at www.sciencedirect.com journal homepage: www.europeanurology.com Collaborative Review Prostate Cancer The Contemporary Concept of Significant Versus Insignificant

More information

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. An Exploration of Risk Stratification for Active Surveillance and Androgen Deprivation Therapy Side Effects for Prostate Cancer Utilizing Data From the Surveillance, Epidemiology, and End Results Database

More information

Prostate-Specific Antigen testing in men between 40 and 70 years in Brazil: database from a check-up program

Prostate-Specific Antigen testing in men between 40 and 70 years in Brazil: database from a check-up program ORIGINAL ARTICLE Vol. 40 (6): 745-752, November - December, 2014 doi: 10.1590/S1677-5538.IBJU.2014.06.05 Prostate-Specific Antigen testing in men between 40 and 70 years in Brazil: database from a check-up

More information

Atypical Foci Suspicious but not Diagnostic of Malignancy in Prostate Needle Biopsies (Also Referred to as Atypical Small Acinar Proliferation

Atypical Foci Suspicious but not Diagnostic of Malignancy in Prostate Needle Biopsies (Also Referred to as Atypical Small Acinar Proliferation european urology 50 (2006) 666 674 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Prostate Cancer Atypical Foci Suspicious but not Diagnostic of Malignancy in Prostate

More information

Age-Specific Reference Ranges for PSA in the Detection of Prostate Cancer

Age-Specific Reference Ranges for PSA in the Detection of Prostate Cancer Age-Specific Reference Ranges for PSA in the Detection of Prostate Cancer Review Article [1] April 01, 1997 By Edward P. Deantoni, PhD [2] PSA is the best tumor marker yet discovered. Age-specific reference

More information

Do 5a-Reductase Inhibitors Alter Prostate Cancer Detection and What Are the Implications?

Do 5a-Reductase Inhibitors Alter Prostate Cancer Detection and What Are the Implications? european urology supplements 5 (2006) 752 757 available at www.sciencedirect.com journal homepage: www.europeanurology.com Do 5a-Reductase Inhibitors Alter Prostate Cancer Detection and What Are the Implications?

More information

Prostate Cancer Screening (PDQ )

Prostate Cancer Screening (PDQ ) 1 di 25 03/04/2017 11.36 NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute

More information

Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland

Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland Protocol applies to invasive carcinomas of the prostate gland. Based on AJCC/UICC TNM, 7 th edition Protocol

More information

Introduction. Original Article

Introduction. Original Article bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after

More information

Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland

Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition, AJCC Staging Manual

More information

Active Surveillance for Prostate Cancer: A Systematic Review of the Literature

Active Surveillance for Prostate Cancer: A Systematic Review of the Literature EUROPEAN UROLOGY 62 (2012) 976 983 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Collaborative Review Prostate Cancer Editorial by Gurdarshan S. Sandhu

More information

Yiannis Philippou 1, Hary Raja 2 and Vincent J. Gnanapragasam 2*

Yiannis Philippou 1, Hary Raja 2 and Vincent J. Gnanapragasam 2* Philippou et al. BMC Urology (2015) 15:52 DOI 10.1186/s12894-015-0049-y RESEARCH ARTICLE Open Access Active surveillance of prostate cancer: a questionnaire survey of urologists, clinical oncologists and

More information

Active Surveillance for Favorable-Risk Prostate Cancer: A Short Review

Active Surveillance for Favorable-Risk Prostate Cancer: A Short Review www.kjurology.org DOI:10.4111/kju.2010.51.10.665 Review Article Active Surveillance for Favorable-Risk Prostate Cancer: A Short Review Nathan Lawrentschuk 1,2, Laurence Klotz 1 1 Department of Urology,

More information

Prostate Cancer Screening

Prostate Cancer Screening Page 1 of 5 The objective of this guideline is to maximize the detection of prostate cancer not to address whether or not early detection is appropriate. It is inherent that if we maximize the detection

More information

Natural History of Prostate Cancer Epidemiologic Considerations

Natural History of Prostate Cancer Epidemiologic Considerations Epidemiologic Reviews Copyright 2001 by the Johns Hopkins University Bloomberg School of Public Health All rights reserved Vol. 23, No. 1 Printed in U.S.A. Natural History of Prostate Cancer Epidemiologic

More information

Infectious complications following transrectal ultrasound (TRUS) - guided prostate biopsy: New challenges in the era of antimicrobial resistance

Infectious complications following transrectal ultrasound (TRUS) - guided prostate biopsy: New challenges in the era of antimicrobial resistance Infectious complications following transrectal ultrasound (TRUS) - guided prostate biopsy: New challenges in the era of antimicrobial resistance ASID Gram-negative Superbugs meeting, 2013 Dr Deborah Williamson

More information

One of the most important clinical applications of

One of the most important clinical applications of PII S0009-9120(99)00099-5 Clinical Biochemistry, Vol. 33, No. 2, 115 123, 2000 Copyright 2000 The Canadian Society of Clinical Chemists Printed in the USA. All rights reserved 0009-9120/00/$ see front

More information

Inflammatory Atrophy on Prostate Needle Biopsies: Is There Topographic Relationship to Cancer?

Inflammatory Atrophy on Prostate Needle Biopsies: Is There Topographic Relationship to Cancer? Clinical Urology Inflammatory Atrophy on Prostate Biopsies and Cancer International Braz J Urol Vol. 33 (3): 355-363, May - June, 2007 Inflammatory Atrophy on Prostate Needle Biopsies: Is There Topographic

More information

Shear Wave Elastography for Detection of Prostate Cancer: A Preliminary Study

Shear Wave Elastography for Detection of Prostate Cancer: A Preliminary Study Original Article Genitourinary Imaging http://dx.doi.org/10.3348/kjr.2014.15.3.346 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2014;15(3):346-355 Shear Wave Elastography for Detection of Prostate Cancer:

More information